Literature DB >> 33871871

Quantifying direct and indirect effect for longitudinal mediator and survival outcome using joint modeling approach.

Cheng Zheng1, Lei Liu2.   

Abstract

Longitudinal biomarkers are widely used in biomedical and translational researches to monitor the progressions of diseases. Methods have been proposed to jointly model longitudinal data and survival data, but its causal mechanism is yet to be investigated rigorously. Understanding how much of the total treatment effect is through the biomarker is important in understanding the treatment mechanism and evaluating the biomarker. In this work, we propose a causal mediation analysis method to compute the direct and indirect effects, when a joint modeling approach is used to take the longitudinal biomarker as the mediator and the survival endpoint as the outcome. Such a joint modeling approach allows us to relax the commonly used "sequential ignorability" assumption. We demonstrate how to evaluate longitudinally measured biomarkers using our method with two case studies, an AIDS study and a liver cirrhosis study.
© 2021 The International Biometric Society.

Entities:  

Keywords:  causal inference; joint modeling; longitudinal data; mediation analysis; survival data

Mesh:

Substances:

Year:  2021        PMID: 33871871      PMCID: PMC8523594          DOI: 10.1111/biom.13475

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   1.701


  23 in total

1.  Evaluating surrogate marker information using censored data.

Authors:  Layla Parast; Tianxi Cai; Lu Tian
Journal:  Stat Med       Date:  2017-01-15       Impact factor: 2.373

2.  Counterfactual links to the proportion of treatment effect explained by a surrogate marker.

Authors:  Jeremy M G Taylor; Yue Wang; Rodolphe Thiébaut
Journal:  Biometrics       Date:  2005-12       Impact factor: 2.571

3.  Defining causal mediation with a longitudinal mediator and a survival outcome.

Authors:  Vanessa Didelez
Journal:  Lifetime Data Anal       Date:  2018-09-14       Impact factor: 1.588

Review 4.  Basic concepts and methods for joint models of longitudinal and survival data.

Authors:  Joseph G Ibrahim; Haitao Chu; Liddy M Chen
Journal:  J Clin Oncol       Date:  2010-05-03       Impact factor: 44.544

5.  Causal mediation analysis on failure time outcome without sequential ignorability.

Authors:  Cheng Zheng; Xiao-Hua Zhou
Journal:  Lifetime Data Anal       Date:  2016-07-27       Impact factor: 1.588

6.  CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group.

Authors:  M D Hughes; M J Daniels; M A Fischl; S Kim; R T Schooley
Journal:  AIDS       Date:  1998-10-01       Impact factor: 4.177

7.  Longitudinal Mediation Analysis with Time-varying Mediators and Exposures, with Application to Survival Outcomes.

Authors:  Wenjing Zheng; Mark van der Laan
Journal:  J Causal Inference       Date:  2017-06-23

8.  A shared random effects model for censored medical costs and mortality.

Authors:  Lei Liu; Robert A Wolfe; John D Kalbfleisch
Journal:  Stat Med       Date:  2007-01-15       Impact factor: 2.373

9.  Mediation analysis when a continuous mediator is measured with error and the outcome follows a generalized linear model.

Authors:  Linda Valeri; Xihong Lin; Tyler J VanderWeele
Journal:  Stat Med       Date:  2014-09-14       Impact factor: 2.373

10.  Derivation and validation of an accurate estimation of CD4 counts from the absolute lymphocyte count in virologically suppressed and immunologically reconstituted HIV infected adults.

Authors:  Barnaby Young; Oon Tek Ng; David Chien Lye; Yee Sin Leo
Journal:  BMC Infect Dis       Date:  2015-08-13       Impact factor: 3.090

View more
  3 in total

1.  Mediation analysis for survival data with High-Dimensional mediators.

Authors:  Haixiang Zhang; Yinan Zheng; Lifang Hou; Cheng Zheng; Lei Liu
Journal:  Bioinformatics       Date:  2021-08-03       Impact factor: 6.931

2.  Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients.

Authors:  Justin de Brabander; Erik Duijvelaar; Job R Schippers; Patrick J Smeele; Hessel Peters-Sengers; Jan Willem Duitman; Jurjan Aman; Harm J Bogaard; Tom van der Poll; Lieuwe D J Bos
Journal:  Eur Respir J       Date:  2022-07-26       Impact factor: 33.795

3.  Modeling the underlying biological processes in Alzheimer's disease using a multivariate competing risk joint model.

Authors:  Floor M van Oudenhoven; Sophie H N Swinkels; Tobias Hartmann; Dimitris Rizopoulos
Journal:  Stat Med       Date:  2022-05-18       Impact factor: 2.497

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.